The idolatry of the surrogate
暂无分享,去创建一个
[1] M. Özkaya,et al. Action to Control Cardiovascular Risk in Diabetes , 2013 .
[2] B. Hemmingsen. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus , 2011, The Cochrane database of systematic reviews.
[3] Russell E. Glasgow,et al. Diabetes Performance Measures: Current Status and Future Directions , 2011, Diabetes Care.
[4] M. Mauer,et al. Olmesartan, microalbuminuria, and type 2 diabetes. , 2011, The New England journal of medicine.
[5] J. Yudkin,et al. Intensified glucose control in type 2 diabetes—whose agenda? , 2011, The Lancet.
[6] Roberta McKean-Cowdin,et al. Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. , 2011, Ophthalmology.
[7] L. Ruilope,et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. , 2011, The New England journal of medicine.
[8] B. Krämer,et al. Olmesartan, microalbuminuria, and type 2 diabetes. , 2011, The New England journal of medicine.
[9] Harlan M Krumholz,et al. Responding to an FDA warning--geographic variation in the use of rosiglitazone. , 2010, The New England journal of medicine.
[10] H. Krumholz,et al. Licensing drugs for diabetes , 2010, BMJ : British Medical Journal.
[11] Rodica Pop-Busui,et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial , 2010, The Lancet.
[12] J. Yudkin,et al. Intensified glucose lowering in type 2 diabetes: time for a reappraisal , 2010, Diabetologia.
[13] Walter T Ambrosius,et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.
[14] Justin W Timbie,et al. Variation in the net benefit of aggressive cardiovascular risk factor control across the US population of patients with diabetes mellitus. , 2010, Archives of internal medicine.
[15] Christine M. Micheel,et al. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease , 2010 .
[16] J. Danesh,et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.
[17] Nick Freemantle,et al. Effect of the quality and outcomes framework on diabetes care in the United Kingdom: retrospective cohort study , 2009, BMJ : British Medical Journal.
[18] N J Wald,et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies , 2009, BMJ : British Medical Journal.
[19] Michael E. Miller,et al. Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.
[20] M. Caulfield,et al. Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.
[21] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[22] Gordon H Guyatt,et al. Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials , 2007, BMJ : British Medical Journal.
[23] J. Diaz. Albuminuria and Risk of Cardiovascular Events, Death, and Heart Failure in Diabetic and Nondiabetic Individuals , 2002 .
[24] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[25] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[26] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[27] N. Chaturvedi,et al. Developing risk stratification charts for diabetic and nondiabetic subjects , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[28] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[29] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[30] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[31] Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. , 1991, Ophthalmology.